Convergence of Human Genetics and Animal Studies: Gene Therapy for X-Linked Retinoschisis.

Retinoschisis is an X-linked recessive genetic disease that leads to vision loss in males. X-linked retinoschisis (XLRS) typically affects young males; however, progressive vision loss continues throughout life. Although discovered in 1898 by Haas in two brothers, the underlying biology leading to blindness has become apparent only in the last 15 years with the advancement of human genetic analyses, generation of XLRS animal models, and the development of ocular monitoring methods such as the electroretinogram and optical coherence tomography. It is now recognized that retinoschisis results from cyst formations within the retinal layers that interrupt normal visual neurosignaling and compromise structural integrity. Mutations in the human retinoschisin gene have been correlated with disease severity of the human XLRS phenotype. Introduction of a normal human retinoschisin cDNA into retinoschisin knockout mice restores retinal structure and improves neural function, providing proof-of-concept that gene replacement therapy is a plausible treatment for XLRS.

[1]  P. Sieving,et al.  Molecular modeling indicates distinct classes of missense variants with mild and severe XLRS phenotypes. , 2013, Human molecular genetics.

[2]  G. Holder,et al.  A phenotype-genotype correlation study of X-linked retinoschisis. , 2013, Ophthalmology.

[3]  Deniz Dalkara,et al.  In Vivo–Directed Evolution of a New Adeno-Associated Virus for Therapeutic Outer Retinal Gene Delivery from the Vitreous , 2013, Science Translational Medicine.

[4]  C. Grimm,et al.  In vivo imaging reveals novel aspects of retinal disease progression in Rs1h(-/Y) mice but no therapeutic effect of carbonic anhydrase inhibition. , 2012, Veterinary Ophthalmology.

[5]  B. Weber,et al.  X-linked juvenile retinoschisis: Clinical diagnosis, genetic analysis, and molecular mechanisms , 2012, Progress in Retinal and Eye Research.

[6]  R. Ali,et al.  Ocular gene delivery using lentiviral vectors , 2011, Gene Therapy.

[7]  P. Sieving,et al.  X-linked retinoschisis: RS1 mutation severity and age affect the ERG phenotype in a cohort of 68 affected male subjects. , 2011, Investigative ophthalmology & visual science.

[8]  L. Vandenberghe,et al.  Novel adeno-associated viral vectors for retinal gene therapy , 2011, Gene Therapy.

[9]  J. Flannery,et al.  AAV mediated GDNF secretion from retinal glia slows down retinal degeneration in a rat model of retinitis pigmentosa. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  W. Hauswirth,et al.  Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  G. Veres,et al.  Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  P. Sieving,et al.  Molecular Modeling of Retinoschisin and Functional Analysis of Pathogenic Mutations From X-Linked Retinoschisis , 2010 .

[13]  P. Sieving,et al.  Molecular modeling of retinoschisin with functional analysis of pathogenic mutations from human X-linked retinoschisis. , 2010, Human molecular genetics.

[14]  W. Hauswirth,et al.  Self-complementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency , 2010, Gene Therapy.

[15]  Jean Bennett,et al.  Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  Kathleen A. Marshall,et al.  Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial , 2009, The Lancet.

[17]  P. Sieving,et al.  Intravitreal delivery of AAV8 retinoschisin results in cell type-specific gene expression and retinal rescue in the Rs1-KO mouse , 2009, Gene Therapy.

[18]  W. Hauswirth,et al.  High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  Kenneth I. Berns,et al.  Gene Therapy Using Adeno-Associated Virus Vectors , 2008, Clinical Microbiology Reviews.

[20]  W. Hauswirth,et al.  Phase I Trial of Leber Congenital Amaurosis due to RPE65 Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results , 2008 .

[21]  Kathleen A. Marshall,et al.  Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[22]  Nick Tyler,et al.  Effect of gene therapy on visual function in Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[23]  Tomohiro Iida,et al.  Resolution of retinoschisis after vitreous surgery in X-linked retinoschisis. , 2008, Ophthalmology.

[24]  P. Sieving,et al.  Retinoschisin gene therapy and natural history in the Rs1h-KO mouse: long-term rescue from retinal degeneration. , 2007, Investigative ophthalmology & visual science.

[25]  M. Trese,et al.  Congenital X-Linked Retinoschisis: Structural and Genetic Evaluation Using a New Classification System , 2007 .

[26]  P. Sieving,et al.  Retinoschisin is a peripheral membrane protein with affinity for anionic phospholipids and affected by divalent cations. , 2007, Investigative ophthalmology & visual science.

[27]  P. Sieving,et al.  Identification and characterization of two mature isoforms of retinoschisin in murine retina. , 2006, Biochemical and biophysical research communications.

[28]  M. Kay,et al.  The 37/67-Kilodalton Laminin Receptor Is a Receptor for Adeno-Associated Virus Serotypes 8, 2, 3, and 9 , 2006, Journal of Virology.

[29]  G. Fishman,et al.  USE OF DORZOLAMIDE FOR PATIENTS WITH X-LINKED RETINOSCHISIS , 2006, Retina.

[30]  C. Ford,et al.  Sensing extracellular matrix: an update on discoidin domain receptor function. , 2006, Cellular signalling.

[31]  P. Campochiaro,et al.  Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. , 2006, Human gene therapy.

[32]  W. Mieler,et al.  Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  W. Hauswirth,et al.  Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of x-linked juvenile retinoschisis. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  Robert W. Williams,et al.  An ENU-induced mutation in Rs1h causes disruption of retinal structure and function. , 2005, Molecular vision.

[35]  T. Kanda,et al.  Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. , 2004, Virology.

[36]  P. Sieving,et al.  A retinal neuronal developmental wave of retinoschisin expression begins in ganglion cells during layer formation. , 2004, Investigative ophthalmology & visual science.

[37]  P. Sieving,et al.  RS-1 Gene Delivery to an Adult Rs1h Knockout Mouse Model Restores ERG b-Wave with Reversal of the Electronegative Waveform of X-Linked Retinoschisis. , 2004, Investigative ophthalmology & visual science.

[38]  Giovanni Di Pasquale,et al.  Identification of PDGFR as a receptor for AAV-5 transduction , 2003, Nature Medicine.

[39]  A. Ciccodicola,et al.  Clinical features of X linked juvenile retinoschisis associated with new mutations in the XLRS1 gene in Italian families , 2003, The British journal of ophthalmology.

[40]  R. Molday,et al.  Defective Discoidin Domain Structure, Subunit Assembly, and Endoplasmic Reticulum Processing of Retinoschisin are Primary Mechanisms Responsible for X-linked Retinoschisis* , 2003, Journal of Biological Chemistry.

[41]  D. Farber,et al.  Retinoschisin, a Photoreceptor-Secreted Protein, and Its Interaction with Bipolar and Müller Cells , 2003, The Journal of Neuroscience.

[42]  P. McDonnell,et al.  Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring. , 2003, Human gene therapy.

[43]  J. Chiorini,et al.  Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. , 2002, Human gene therapy.

[44]  M. Seeliger,et al.  Inactivation of the murine X-linked juvenile retinoschisis gene, Rs1h, suggests a role of retinoschisin in retinal cell layer organization and synaptic structure , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[45]  B. Weber,et al.  Expression of X-linked retinoschisis protein RS1 in photoreceptor and bipolar cells. , 2001, Investigative ophthalmology & visual science.

[46]  P. Sieving,et al.  P23H rhodopsin transgenic rat: correlation of retinal function with histopathology. , 2000, Investigative ophthalmology & visual science.

[47]  P. Sieving,et al.  Phenotypic expression of juvenile X-linked retinoschisis in Swedish families with different mutations in the XLRS1 gene. , 2000, Archives of ophthalmology.

[48]  Juliet A. Ellis,et al.  Retinoschisin, the X-linked retinoschisis protein, is a secreted photoreceptor protein, and is expressed and released by Weri-Rb1 cells. , 1999, Human molecular genetics.

[49]  C. Kozak,et al.  The mouse X-linked juvenile retinoschisis cDNA: expression in photoreceptors. , 1999, Gene.

[50]  P. Sieving,et al.  Functional implications of the spectrum of mutations found in 234 cases with X-linked juvenile retinoschisis (XLRS) , 1998 .

[51]  R. Samulski,et al.  Membrane-Associated Heparan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Virus Type 2 Virions , 1998, Journal of Virology.

[52]  J. Bennett,et al.  Real-time, noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction. , 1997, Investigative ophthalmology & visual science.

[53]  B. Lorenz,et al.  Positional cloning of the gene associated with X-linked juvenile retinoschisis , 1997, Nature Genetics.

[54]  A. Moore,et al.  X linked retinoschisis. , 1995, The British journal of ophthalmology.

[55]  A. Munnich,et al.  Contribution to carrier detection and genetic counselling in X linked retinoschisis. , 1991, Journal of medical genetics.

[56]  M. Brigell,et al.  Psychophysical and electroretinographic findings in X-linked juvenile retinoschisis. , 1987, Archives of ophthalmology.

[57]  I. Mann,et al.  CONGENITAL VASCULAR VEILS IN THE VITREOUS , 1938, The British journal of ophthalmology.

[58]  Marjan Wilczek Ein Fall der Netzhautspaltung (Retinoschisis) mit einer öffnung , 1935 .

[59]  A. Heiligenhaus Acetazolamide in the Treatment of X-Linked Retinoschisis Maculopathy , 2007 .

[60]  R. Samulski,et al.  AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. , 1999, Nature medicine.

[61]  P. Sieving,et al.  Juvenile retinoschisis: a model for molecular diagnostic testing of X-linked ophthalmic disease. , 1999, Transactions of the American Ophthalmological Society.

[62]  R. Samulski,et al.  αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection , 1999, Nature Medicine.

[63]  S. Walpole Functional implications of the spectrum of mutations found in 234 cases with X-linked juvenile retinoschisis. The Retinoschisis Consortium. , 1998, Human molecular genetics.

[64]  C. Giraud,et al.  Biology of adeno-associated virus. , 1996, Current topics in microbiology and immunology.